Phase II Study With CC-10004 in Psoriatic Arthritis
This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in
patients with active psoriatic arthritis. The pharmacokinetics of the compound in patients
will also be explored, and biopsies will be taken of the skin and the knee synovium to look
at the activity of the drug in the relevant tissues.
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open label study for patients with severe plaque type psoriasis. This study is looking to
evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the
epidermal thickness in subjects with severe placque type psoriasis.
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe
psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The
information obtained from the study will aid in the design of future clinical trials and to
establish the safety and efficacy of CC-10004.
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
Phase 1/Phase 2
The purpose of this study is to determine the clinical and immunological effects of the
phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.